Anxiety and end-of-life distress are among the earliest and most studied areas in modern psilocybin research. Scientists began focusing on these conditions because they are often difficult to treat with conventional therapies, particularly in patients facing life-threatening illnesses. Research in this area has been conducted through carefully controlled clinical trials with extensive psychological support.
One of the most influential modern studies was published in 2016 in the Journal of Psychopharmacology by researchers at Johns Hopkins University. This randomized, double-blind trial examined psilocybin-assisted therapy in patients with life-threatening cancer diagnoses and found significant reductions in anxiety and depressive symptoms. Importantly, the authors emphasized that outcomes were tied to structured preparation, supervised sessions, and integration support rather than the compound alone (Griffiths et al., Journal of Psychopharmacology, 2016).
Around the same time, researchers at New York University conducted a similar randomized controlled trial, published in the Journal of Psychopharmacology. This study also reported sustained reductions in anxiety and depression in cancer patients following psilocybin-assisted therapy. The researchers highlighted the importance of clinical screening and professional support in reducing risk and variability (Ross et al., Journal of Psychopharmacology, 2016).
Long-term follow-up data from these trials has also been published. A study released in 2020 by Johns Hopkins researchers examined participants up to four and a half years after treatment and found that many reported sustained reductions in anxiety and depression related to their cancer diagnosis. Researchers cautioned that these findings do not imply permanence or universal benefit, but they do demonstrate lasting effects in some patients under clinical conditions (Agin-Liebes et al., Journal of Psychopharmacology, 2020).
Scientists studying end-of-life distress emphasize that psilocybin is not used to treat the underlying medical illness. Instead, research focuses on psychological well-being, emotional processing, and quality-of-life measures. The National Cancer Institute notes that addressing emotional distress is an important part of comprehensive cancer care, which helps explain interest in adjunctive therapies within regulated research frameworks (National Cancer Institute).
Researchers consistently stress that these results cannot be generalized beyond clinical settings. Participants in these trials were carefully screened, monitored, and supported throughout the process. The National Institute of Mental Health explains that anxiety disorders and end-of-life distress involve complex biological and psychological factors, and investigational therapies must be evaluated cautiously across broader populations (National Institute of Mental Health).
High Science® presents this research to clarify what has been studied, what outcomes have been observed, and where limitations remain. By grounding discussions of anxiety and end-of-life distress in peer-reviewed evidence, this educational approach supports informed, compassionate, and science-based advocacy.
SOURCES
Griffiths et al., Journal of Psychopharmacology (2016) – Cancer-related anxiety and depression
Ross et al., Journal of Psychopharmacology (2016) – Psilocybin-assisted therapy for cancer patients
Agin-Liebes et al., Journal of Psychopharmacology (2020) – Long-term follow-up study
National Cancer Institute – Anxiety and cancer care
National Institute of Mental Health – Anxiety disorders overview
All information presented is for educational purposes only and focuses on plant science research and emerging studies. This content does not replace professional medical advice. Always consult licensed healthcare providers or trained professionals in plant-based science and natural health disciplines. All information provided is thought to be put to date with modern research and you should still do your own research and consult with professionals.
